Lundbeck and Genmab work on antibodies for central nervous system

10/13/2010 | Reuters

Genmab stands to receive as much as $53.5 million, including $10.4 million upfront, from H. Lundbeck in a deal to develop human antibodies to treat diseases affecting the central nervous system. The collaboration provides Lundbeck access to Genmab's human-antibody technology UltiMab, allowing it "to pursue valuable [central nervous system] targets otherwise not accessible."

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR